EU/3/15/1458 - orphan designation for treatment of ovarian cancer
Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4
OrphanHuman
Overview
On 19 March 2015, orphan designation (EU/3/15/1458) was granted by the European Commission to ImmunoGen Europe Limited, United Kingdom, for humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 for the treatment of ovarian cancer.
Ovarian cancer is cancer of the ovaries, the two organs in the female reproductive system that produce eggs. Most ovarian cancers occur in women over the age of 50 years. Due to the absence of symptoms in the early stages of the disease, the majority of patients are diagnosed when the cancer has spread to other parts of the body.
Ovarian cancer is a long-term debilitating and life-threatening disease that is associated with poor long-term survival.
At the time of designation, ovarian cancer affected not more than 3 in 10,000 people in the European Union (EU). This was equivalent to a total of not more than 154,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).
At the time of designation, several medicines were authorised in the EU for the treatment of ovarian cancer. The choice of treatment depended mainly on how advanced the disease was. Treatments included surgery and chemotherapy (medicines to treat cancer).
The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with ovarian cancer because early studies showed that it may improve the outcome of patients whose disease did not respond or had come back after previous treatment. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
This medicine is made up of two active components, which are linked together:
- a monoclonal antibody (a type of protein) that has been designed to recognise and attach to certain receptors called folate receptors 1, which are present in high amounts on certain cancer cells including some ovarian cancer cells.
- maytansinoid DM4, a toxic substance that kills cells when they attempt to divide and grow. DM4 attaches to a protein in cells called 'tubulin', which is important in the formation of the internal 'skeleton' that cells need to assemble when they divide. By attaching to tubulin in cancer cells, DM4 stops the formation of this skeleton, preventing the division and growth of the cancer cells.
The medicine is expected to attach to the folate receptor of the cancer cell and enter the cell. The medicine is then expected to release the maytansinoid DM4 component inside the cell, causing it to die.
The effects of the medicine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with ovarian cancer were ongoing.
At the time of submission, the medicine was not authorised anywhere in the EU for ovarian cancer. Orphan designation of the medicine had been granted in the United States for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 12 February 2015recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4
- Intended use
- Treatment of ovarian cancer
- Orphan designation status
- Positive
- EU designation number
- EU/3/15/1458
- Date of designation
- Sponsor
AbbVie Deutschland GmbH & Co. KG
Update history
| Date | Update |
|---|---|
| May 2024 | The sponsorship was transferred to Abbvie Deutschland GmbH & Co. KG. |
| May 2019 | The sponsorship was transferred to ImmunoGen BioPharma (Ireland) Limited, Ireland, in May 2019. |
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: